Cell4Cure

Cell4Cure AB, a Swedish biotech company founded in 2023, is pioneering immune tolerance therapies aimed at addressing significant clinical challenges such as anti-drug antibodies (ADAs), autoimmune diseases, and transplant rejection. The company’s proprietary platform leverages ex vivo-generated dendritic cells (DCs) engineered to induce antigen-specific immune tolerance. These tolerogenic DCs offer a targeted approach to mitigating unwanted immune responses while preserving essential immune functions.

Cell4Cure’s primary focus is on ADAs, a critical issue in conditions like severe hemophilia A, where 30% of patients develop neutralizing antibodies against factor VIII (FVIII) treatments. With our lead product, ItolDC-028, we are ready to initiate a Phase 1/2a clinical trial in Europe to evaluate its safety and efficacy in hemophilia A patients with ADAs. This innovative therapy aims to restore responsiveness to FVIII, providing an alternative to conventional immune tolerance induction therapies.

Based on $30 million in R&D investments, the technology platform has reached key development milestones including EMA approval for a clinical trial and a robust GMP manufacturing process. Additionally, Cell4Cure’s patented technology platform has the potential to extend its applications to autoimmune diseases and transplant immunology, positioning the company at the forefront of personalized medicine and immune tolerance research.